INSP 196.24 Inspire Medical Systems, Inc.
| Range: | 123.0-257.4 | Vol Avg: | 647190 | Last Div: | 0 | Changes: | 5.39 |
| Beta: | 1.34 | Cap: | 6.29B | Currency: | USD | Exchange: | NYSE |
| Sector: | Healthcare | IPO: | Thu May 03 2018 | Empoloyees: | 1011 | ||
| CUSIP: | 457730109 | CIK: | 0001609550 | ISIN: | US4577301090 | Country: | US |
| CEO: | Mr. Timothy P. Herbert | Website: | https://www.inspiresleep.com | ||||
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, a closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.
Stock Details
INSP 240
Inspire Medical Systems (INSP) PT Raised to $240 at Baird
David Rescott·Tue Oct 15 2024
Robert W. Baird
INSP 230
Inspire Medical Systems (INSP) PT Lowered to $230 at Jefferies
Michael Sarcone·Mon Jul 29 2024
Jefferies
INSP 217
Inspire Medical price target lowered to $217 from $280 at Truist
Richard Newitter·Tue Jul 16 2024
Truist Financial
INSP 210
Inspire Medical price target lowered to $210 from $250 at Morgan Stanley
Kallum Titchmarsh·Mon Jul 15 2024
Morgan Stanley
INSP 255
Piper Sandler Reiterates Overweight Rating on Inspire Medical Systems (INSP)
Adam Maeder·Tue Jun 25 2024
Piper Sandler
INSP 170
Inspire Medical price target lowered to $170 from $210 at Stifel
Jonathan Block·Mon Jun 24 2024
Stifel Nicolaus
INSP 175
Inspire Medical Systems (INSP) PT Lowered to $175 at CFRA
Paige Meyer·Tue Jun 11 2024
CFRA
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow